Besides IGF-1/PI3K signaling, several glioma cell-derived factors, such as GM-CSF and IFN-γ, seem to protect GAMs from CSF-1R inhibitor-mediated depletion and thereby mediate therapy resistance [97]. The gene discussed is CSF1R; the disease is central nervous system cancer.